Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.
CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state of the art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.
The company was founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti; and has since built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, while also establishing strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute.
Company Growth (employees)
Key People at Cancer Genetics
Panna Sharma
Cancer Genetics Office Locations
Cancer Genetics Data and Metrics
Cancer Genetics Financial Metrics
Revenue (FY, 2016) | 27 m |
Revenue growth (FY, 2015 - FY, 2016), % | 50% |
Gross profit (FY, 2016) | 9.9 m |
Gross profit margin (FY, 2016), % | 37% |
Net income (FY, 2016) | (15.8 m) |
EBIT (FY, 2016) | (16.7 m) |
Market capitalization (26-May-2017) | 74.7 m |
Closing share price (26-May-2017) | 4 |
Cash (31-Dec-2016) | 9.5 m |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 6.6 m | 10.2 m | 18 m | 27 m |
Revenue growth, % | 54% | 77% | 50% | |
Cost of goods sold | 4.9 m | 8.5 m | 14.1 m | 17.1 m |
Gross profit | 1.7 m | 1.7 m | 3.9 m | 9.9 m |
Gross profit Margin, % | 25% | 17% | 22% | 37% |
Operating expense total | 10.1 m | 21 m | 25.3 m | 26.7 m |
EBIT | (8.4 m) | (18.3 m) | (20.7 m) | (16.7 m) |
EBIT margin, % | (128%) | (179%) | (115%) | (62%) |
Interest expense | (2.4 m) | (472.8 k) | (344 k) | 454 k |
Interest income | 29.7 k | 73.8 k | 49 k | 23 k |
Pre tax profit | (13 m) | (19 m) | (21.4 m) | (15.8 m) |
Income tax expense | (663.9 k) | (2.4 m) | ||
Net Income | (12.4 m) | (16.6 m) | (20.2 m) | (15.8 m) |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 49.5 m | 25.6 m | 19.5 m | 9.5 m |
Accounts Receivable | ||||
Inventories | ||||
Current Assets | 51.9 m | 31.8 m | 28.2 m | 23.4 m |
PP&E | 1.3 m | 4.4 m | 6.1 m | 4.7 m |
Goodwill | 3 m | 12 m | 12 m | |
Total Assets | 55.2 m | 47.1 m | 48.9 m | 42.4 m |
Accounts Payable | 2.3 m | 3.8 m | 7.6 m | 8.1 m |
Current Liabilities | 8.6 m | 4.4 m | 9.9 m | 11 m |
Preferred Stock | ||||
Additional Paid-in Capital | 106.8 m | 112.5 m | 131.2 m | 139.6 m |
Retained Earnings | (61.3 m) | (98.2 m) | (114 m) | |
Total Equity | 45.5 m | 33 m | 25.6 m | |
Financial Leverage | 1.2 x | 1.5 x | 1.7 x |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (12.4 m) | (16.6 m) | (20.2 m) | (15.8 m) |
Depreciation and Amortization | 311.2 k | 810.2 k | 1.5 m | 2 m |
Accounts Receivable | (716.5 k) | (1.7 m) | (1.7 m) | (5.9 m) |
Inventories | ||||
Accounts Payable | ||||
Cash From Operating Activities | 48.6 m | (23.9 m) | (6.1 m) | |
Purchases of PP&E | (257.3 k) | (1.4 m) | (1 m) | (490 k) |
Cash From Investing Activities | (1.4 m) | (11.4 m) | (2.6 m) | (609 k) |
Short-term Borrowings | (3.6 m) | (408.4 k) | (1.3 m) | |
Cash From Financing Activities | 58.1 m | 10.1 m | 8.5 m | |
Interest Paid | 608.1 k | 128.4 k | 240 k | 333 k |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.7 x |
